Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective

References

• World Health Organization. World Health Organization-Diabetes. Geneva: World Health Organization, 2013. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 15 August 2013
   Google Scholar
• Gardete Correia L, Boavida JM, Fragoso de Almeida JP, et al. Diabetes: Factors e números 2012. Relatório anual do observatório nacional da diabetes. Portugal. Lisboa: Sociedade Portuguesa de Diabetologia, 2013
   Google Scholar
• Andayani TM, Ibrahim MIM, Asdie AH. Assessing the impact of complications on the direct medical costs of Type 2 diabetes mellitus outpatients. Int J Curr Pharm Res 2010;2:32-5
   Google Scholar
• Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm 2010;16:264-75
   PubMed Web of Science ®Google Scholar
• Oglesby AK, Secnik K, Barron J, et al. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006;4:1
   PubMedGoogle Scholar
• Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010;33:1903-4
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123(3 Suppl):S12-18
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Profit L, Chrisp P, Nadin C. Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2008;3:13-30
   PubMedGoogle Scholar
• Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
   PubMed Web of Science ®Google Scholar
• Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-9
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675-82
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS. A critique of the 2012 ADA/EASD position statement. Diabetologia 2012;55:2850-2
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• Liu S, Zhao Y, Hempe JM, et al. Economic burden of hypoglycemia in patients with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res 2012;12:47-51
   PubMed Web of Science ®Google Scholar
• Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey. Expert Rev Pharmacoecon Outcomes Res 2013;13(1):123-30
   Google Scholar
• Calado F, Gruenberger J-B, de Nigris E, et al. Cost-effectiveness of vildagliptin compared to generic sulphonylureas added on to metformin from a Portuguese healthcare system perspective. Poster #1199-P. Philadelphia, PA: 72nd American Diabetes Association Congress, 2012
   Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Direção-Geral de Saúde. Norma 052/2011 da Direção-Geral de Saúde. Abordagem Terapêutica Farmacológica na Diabetes tipo 2. 2013 Jul 30. Report No.: 052/2011
   Google Scholar
• Cabrita J, Lopes MM, de Oliveira Martins S, et al. Perfil de prescriçäo e avaliaçäo do grau de cumprimento de orientaçöes terapêuticas em diabéticos tipo 2: Estudo transversal em medicina geral e familiar. Rev Port Farmacoter 2011;3:7-13
   Google Scholar
• Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 2002;19:465-9
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Manns B, Meltzer D, Taub K, et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ 2003;12:949-58
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012;32:189-202
   PubMed Web of Science ®Google Scholar
• Infarmed. Orientaçòes metodológicas para estudos de avaliaçäo económica de medicamentos. Lisbon: Infarmed – Autoridade Nacional do Medicamento e Produtos em Saúde I.P., 1998
   Google Scholar
• Zhang P, Zhang X, Brown JB. Economic impact of diabetes. IDF Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation, 2013
   Google Scholar
• International Diabetes Federation. Diabetes Atlas 2012. Brussels: International Diabetes Federation, 2013. http://www.idf.org/diabetes-atlas-2012-update-out-now. Accessed September 23, 2013
   Google Scholar
• Yazdanpanah Y, Perelman J, Dilorenzo MA, et al. Routine HIV Screening in Portugal: clinical impact and cost-effectiveness. PLoS One 2013;8:e84173
   PubMed Web of Science ®Google Scholar
• Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. London: London School of Economics, 2012
   Google Scholar
• Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(1 Suppl):43-55
   PubMed Web of Science ®Google Scholar
• Tilden DP, Mariz S, O'Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54
   PubMed Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-9
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS Health Moving Annual Target (MAT) for Antidiabetics in Portugal from June 2012 to June 2013. Porto Salvo: IMS Health, 2013
   Google Scholar
• Infarmed. Autoridade Nacional do Medicamento e Produtos de Saúde I.P. Lisbon, 2014
   Google Scholar
• Ministérios da Economia e do Emprego e da Saúde. Despacho no. 4294-A/2013. Ministérios da Economia e do Emprego e da Saúde. Lisbon, 2013
   Google Scholar
• Pereira R, Gouveia M, Martins AP. Análise custo-efectividade de sitagliptina quando adicionada e metformina em doentes com diabetes tipo 2 em Portugal. Revista Portuguesa de Diabetes 2012;7:13-23
   Google Scholar
• Ministério da Saúde. Portaria 163. Portaria n.° 163. (2013) Diário da República. Lisbon, 2013
   Google Scholar
• Portugal S, Martins B, Ramos L, et al. Estudo de Avaliação do Impacto dos Custos Financeiros e Sociais da Deficiência. Relatório Final. Coimbra: Centro de Estudos Sociais, Instituto Nacional de Reabilitação, Ministério do Trabalho e da Solidariedade Social, 2010
   Google Scholar
• Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar
• Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50
   PubMed Web of Science ®Google Scholar